Advanced HIV Disease Burden in Selected Health Facilities in Mozambique, October–December 2023

Alexandre Nguimfack,Eudoxia Filipe,Dercio Filimao,Jose Mizela,Erica Bila,Mercia Matsinhe,Maria Ines M Tomo De Deus,Irenio Gaspar,Maria Ruano,Luis Armando,Orrin M Tiberi
DOI: https://doi.org/10.1101/2024.11.26.24317679
2024-11-28
Abstract:Introduction: Advanced HIV Disease (AHD) is a remaining hurdle in the care and treatment cascade in Mozambique and has the potential to delay Mozambiques progress towards the UNAIDS 95-95-95 goals for 2025. An improved understanding of the prevalence and demographics of AHD is critical to understanding this important condition. Methods: Aggregated routine data from October to December 2023 were reviewed from the 79 health facilities implementing the AHD diagnosis and treatment package at the national level. Results: Overall, 36% (7,811/21,452) of people living with HIV (PLHIV) newly initiated or reinitiated on treatment had a CD4 test, of which 1,986 were diagnosed with AHD. Most people with AHD were newly initiating ART (1,814), and few were reinitiating ART (179). Conclusion: Low CD4 testing uptake means that AHD remains a challenge towards the elimination of HIV as a public health threat in Mozambiques path.
HIV/AIDS
What problem does this paper attempt to address?